In 2025, biotech firms face rising cyber threats targeting R&D data—now a prime asset for attackers. This article outlines why traditional security isn’t enough and urges biotech leaders to embed cybersecurity into every phase of innovation to protect IP, partnerships, and long-term competitiveness.

Biotech firms are being targeted. Hackers no longer only target customer information or financial details. They are currently focusing on R&D data, which is the most important asset that biotech companies possess. This contains secret clinical trial results, AI-driven chemical predictions, medication formulations, simulation models, and unique genetic research.

In 2025, biotech firms must treat cybersecurity as a foundational business function, not a back-office expense. IT and security leaders must shift their focus from general protection to safeguarding the intellectual core of the company. As USDM Life Sciences recently reported, attackers increasingly target gaps in biotech’s research infrastructure, not just traditional enterprise systems.

Why R&D Data Is Now the Primary Target

Biotech innovation relies on massive volumes of sensitive data. Each breakthrough, from mRNA sequencing to gene therapies, stems from years of clinical trials, AI modeling, and data collaboration. Protecting this data is more than risk management—it’s essential for survival.

NCBI’s recent threat briefing shows a 64% increase in biotech-focused attacks over the last year. The data most sought after isn’t just customer-related—it’s intellectual property, unpublished studies, and early-stage trial findings. Once stolen, this data can’t be replaced or recalled. Competitors can fast-track development. Criminals can sell it to the highest bidder. Governments can use it to build unauthorized versions of advanced therapies.

The complexity of R&D environments makes them particularly vulnerable. Researchers need fast access to datasets, which means security controls are often bypassed or weakened. Labs rely on connected instruments, cloud analytics, and global partnerships—all of which expand the attack surface.

ScienceDirect 2025 Biosecurity Audit found that over 70% of biotech firms still lack centralized oversight of their lab systems. Many research teams use unmanaged collaboration platforms, often syncing sensitive data without encryption or audit trails. A simple misconfigured S3 bucket or outdated lab workstation can expose terabytes of confidential R&D material.

The digital transformation of biotech has outpaced its cybersecurity transformation. Now, attackers are exploiting that gap.

Real-World Breaches That Exposed the Risk

The threat is not theoretical. Several recent breaches have highlighted how cyberattacks targeting R&D data can disrupt business, delay innovation, and damage long-term value.

Case 1: 10x Genomics (California)

In Q4 2024, 10x Genomics detected unauthorized access within its development environment. The breach originated from misconfigured permissions in a staging environment on AWS. Cybercriminals quietly exfiltrated proprietary simulation data linked to its next-generation single-cell technology. Though operations continued, the breach forced the company to delay an upcoming product launch and reevaluate its cloud access policies. KingsGuard later confirmed that data related to this breach surfaced in underground marketplaces in early 2025.

Case 2: Beam Therapeutics (Massachusetts)

 In January 2025, Beam reported a suspected intrusion via one of its academic research partners. Attackers had exploited a partner VPN, gaining lateral access to internal research tools linked to CRISPR editing trials. Fortunately, security teams caught the intrusion during routine anomaly detection. No confirmed data exfiltration occurred, but the investigation revealed poor segmentation between external access and lab systems. Beam has since implemented Zero Trust controls and overhauled its third-party risk program.

Case 3: Evotec (Global, with U.S. operations)

Evotec, which collaborates with numerous U.S.-based pharmaceutical and biotech firms, faced a ransomware attack in early 2025. While the attack appeared financially motivated, logs showed attempts to access structured datasets from diabetes and metabolic disease research. The attack led to a multi-day shutdown of research operations, affecting timelines for several collaborative drug discovery projects. These incidents highlight how adversaries are increasingly bypassing public-facing systems and going straight for biotech’s digital core—its R&D environments.

The Cybersecurity Actions Biotech Must Take Now

Protecting biotech R&D data takes everything beyond a firewall or antivirus. It calls for integrated, proactive, and smart protection that’s built into the research life cycle. CISOs and CIOs need to act across several fronts to close the gaps.

1. Map and Monitor Your R&D Data Flows

Begin with end-to-end visibility. See where all the pieces of key research data live, how it flows between systems, and who touches it. That means LIMS, ELNs, cloud modeling software, and even networked lab equipment. Most breaches don’t stem from a single failure, but from cumulative blind spots between disconnected tools, systems, and teams.

2. Mandate Strict Access Controls and Segmentation

Use role-based access controls to restrict data visibility by function. Researchers would only see datasets that are pertinent to their projects. Implement network segmentation between research environments, production systems, and corporate IT infrastructure. Beam’s containment of its VPN intrusion illustrates how segmentation can contain damage.

3. Protect Third-Party and Partner Access

All external partners are potential risk vectors. Screen all vendors and collaborators for security maturity. Mandate security certifications such as SOC 2 Type 2 or ISO 27001, especially for cloud storage, analytics platforms, and CROs. USDM Life Sciences suggests that biotech firms have formal cyber-risk SLAs with all research partners and cloud service providers.

4. Encrypt Everything—At Rest and In Transit

Most lab systems continue not to encrypt transmissions or files. Replace outdated systems that are incapable of meeting today’s standards. Demand end-to-end encryption of file transfers within internal teams and with external partners. Cloud providers need to provide support for internally managed and rotated encryption keys.

5. Deploy Real-Time Threat Detection Tools

Install tools for anomaly detection and behavioral analytics that are aware of biotech workflows. These tools should flag unusual file access, large data transfers, or new devices joining the lab network. CyberSniper.ai’s specialized biotech detection suite includes indicators for exfiltration of genomic data or AI model weights—critical assets attackers now target.

6. Train Research Staff on Cybersecurity Protocols

Most laboratory-based personnel are not security experts. However, they are high-value targets due to their access levels. Phishing threats, password hygiene, and secure data handling training can be done regularly to avoid accidental compromises. Insider threat scenarios should also be simulated in real-world situations to check response readiness.

Key Takeaways for Biotech Leaders

Treat R&D data like a crown jewel asset:

Defend intellectual property as an executive-level priority. Use the same level of cyber protection on research data that you would for financial and operations systems.

Align security approaches with scientific workflows.

Establish cybersecurity policies on how research groups operate. Make protective safeguards not interrupt innovation or data-driven experimentation.

Form strong security partnerships.

Partner with CROs, academic institutions, and technology vendors on joint security objectives. Demand formal security policies, SLAs, and ongoing risk assessments across the ecosystem.

Enforce real-time visibility and monitoring.

Installs tools that provide full visibility to research environments. Monitor data movement, access points, and anomalies across cloud, lab systems, and partner platforms.

Emphasize security talent with data science fluency

Employ cybersecurity experts who are familiar with the specific data models, processes, and software employed in biotech R&D. Scientific proficiency among your security personnel is a must.

Biotech companies can’t tolerate blind spots. A single breach could undermine decades of research. By 2025, cybersecurity should be an enabler of business, not an incident response IT department. Data safeguarding in R&D is the basis for sustained, secure innovation.

FAQs

Q1. Why is R&D data the main target in Cybersecurity in BioTech today?

R&D data holds massive commercial and scientific value in biotech, containing proprietary research, clinical trials, and AI models. Unlike financial data, it’s irreplaceable once stolen. Cybercriminals, competitors, and nation-states target it to fast-track drug development or monetize breakthroughs. As biotech digitizes faster than it protects, these assets have become prime targets and require quick cybersecurity reinforcement.

Q2. How can weak third-party access impact Cybersecurity in BioTech?

External research partners and vendors often lack strong cybersecurity practices. Unsecured VPNs, outdated collaboration tools, or missing SLAs can become entry points for attackers to access internal R&D data. A single partner’s vulnerability can compromise entire research ecosystems. Effective cybersecurity in biotech demands strict vetting, segmentation, and continuous monitoring of third-party systems to reduce exposure.

Q3. What are the biggest threats to R&D data in biotech firms?

Major threats include unauthorized access, insider misuse, misconfigured cloud storage, phishing attacks, and ransomware. Sophisticated attacks often exploit gaps in lab systems or collaboration tools to steal or corrupt data. Since R&D data isn’t easily replaced, these breaches can delay innovation, disrupt partnerships, and lead to regulatory issues, making proactive protection non-negotiable.

Q4. How can biotech companies secure their R&D environments effectively?

Biotech firms must enforce role-based access, encrypt data at rest and in transit, segment networks, and deploy real-time threat detection tailored to research workflows. Centralizing visibility across lab systems and cloud tools is critical. Investing in staff training and partnering only with security-compliant vendors further strengthens the R&D cybersecurity framework across the innovation lifecycle.

Q5. Why should leadership prioritize Cybersecurity in BioTech R&D initiatives?

Leaders in the biotech industry must view cybersecurity as an essential component of innovation rather than a side IT issue. Protecting R&D data safeguards competitive edge, investor trust, and long-term pipeline value. Executive prioritization ensures aligned budgets, talent, and policy enforcement. In 2025’s high-stakes digital biotech landscape, cyber resilience is vital to sustaining growth and scientific progress without disruption.

To share your insights, please write to us at sudipto@intentamplify.com